Skip to content

in the Future
of Medicine

We create and invest in biotech companies with innovative technologies that are developing life-saving drugs for patients. We invest in both private and public companies, providing a unique longitudinal view of drug development across the industry.


30+ Years of Biotech Investing
57 FDA-approved drugs
39 Companies founded since 2010*


Companies created by MPM BioImpact include portfolio companies where MPM BioImpact was a co-founder or early lead investor from 2010 to today, representing the period that MPM BioImpact’s strategy has been focused on company creation.

We are Company Creators

Our team of scientists identifies innovative technologies and brings ideas to life by building companies from the ground up. We translate research into clinically meaningful drugs and potential cures.

In 2014, Doug Melton, Ph.D., Director of the Harvard Stem Cell Institute and long-standing academic relationship with the MPM BioImpact team, made a groundbreaking research finding enabling the generation of human pancreatic beta cells from pluripotent stem cells, facilitating a potentially curative cell therapy for type 1 diabetes. Based on this discovery, MPM BioImpact, led by Managing Director Todd Foley, M.B.A., founded and incubated Semma Therapeutics alongside Dr. Melton and led the 2015 Series A round.

i. The case study above is for illustrative purposes only and was not selected based on the performance of such investment. Rather, it is shown as a representative example of a company that MPM BioImpact created and built. This investment represents a portion of MPM BioImpact’s portfolio and is not intended to be representative of future investments.




Meet our Team

MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. Our Entrepreneur Partners provide deep domain expertise as investor-operators and work with our diverse group of scientists and professionals to develop therapies for diseases with high unmet needs. Collectively, we are a team of deeply experienced company creators who help transform scientific discoveries into breakthrough medicines for the patients that need them most.

Learn about our team of experts

Our Portfolio

Adaptimmune Logo
Aktis Logo
Antiva Biosciences Logo
Arialys Logo
AshiBio Logo
AstronauTx Logo
Crossbow Therapeutics Logo
Cullinan Oncology Logo
Deka Biosciences Logo
digiTx Partners Logo
Dyne Therapeutics Logo
elevatebio Logo
Entrada Therapeutics, Inc. Logo
Firefly Logo
Frontier Medicines Logo
iTeos Logo
NextPoint Therapeutics Logo
Photys Therapeutics, Inc. Logo
Protego Logo
Recode TX Logo
Redona Therapeutics Logo
ReNAgade Therapeutics Logo
Repare Therapeutics, Inc. (RPTX) Logo
Reunion Neuroscience Logo
Tetherex Pharmaceuticals Corporation Logo
Tizona Therapeutics, Inc. Logo
Trishula Therapeutics, Inc. Logo
Umoja Biopharma, Inc. Logo
Werewolf Therapeutics, Inc. (HOWL) Logo
Portfolio Companies